"Will Gene Patents Derail the Next-Generation of Genetic Technologies?: A Reassessment of the Evidence Suggests Not," 80 UMKC Law Review 563 (2012); "Misplaced Fears in the Legislative Battle Over Affordable Biotech Drugs," 50 IDEA: The Journal of Law and Technology (2010, Energy Center Research Paper No. 12-01); "Learning from Litigation: What Can Lawsuits Teach Us About the Role of Human Gene Patents in Research and Innovation?" 18 Kansas Journal of Law & Public Policy 215 (2009); "The Impact of Human Gene Patents on Innovation and Access: A Survey of Human Gene Patent Litigation," 76 UMKC Law Review 295 (2007).
Intellectual property, antitrust, food and drug, biotechnology
J.D., Boalt Hall School of Law (UC-Berkeley), 1998; Ph.D., University of California, Davis, 1993; B.A., California State University, Hayward, 1987.
Assistant to Director of Intellectual Property and Licensing, Somatix Therapy Corporation, 1996; Patent Agent, Flehr Hohbach LLP, 1996-1997; Summer Associate and Associate, Pennie & Edmonds LLP, 1997, 1998-1999; Judicial Extern to Judge Claudia Wilken, Federal District Court, Northern District of California, 1997; Associate Patent Counsel, Transgenomic Inc., 2000-2001; Patent Counsel, Maxygen Inc., 2001-2002; Vice President of Intellectual Property, PhyNexus Inc., 2003-2005; Associate Professor, UMKC School of Law, 2005-present.